Invuity develops Intelligent Photonics™ devices and a broad product line of advanced visualization devices aimed at transforming care for minimal access surgery. Clinical applications cited include breast and thyroid oncology, plastics, spine, orthopedic, cardiothoracic and general surgery. Led by President and CEO Philip Sawyer, the company positions its technology to create a new standard of care in those surgical domains. The company intends to use newly raised capital to accelerate growth and to further commercial initiatives across its product line. Financially, Invuity closed a $20m funding round to support those commercial and growth plans. Invuity develops advanced medical devices that improve access and visualization in minimally invasive and minimal access surgeries. Its products incorporate proprietary Eigr technology into hand-held illumination devices and access systems for specialties including spine, orthopedics, breast and thyroid oncology, and plastic surgery. The company is headquartered in San Francisco, CA. Invuity reported that revenue has been more than doubling each year. Management says the recent financing will be used to accelerate commercial initiatives, accelerate product introductions, and expand the commercialization team. The deal structure combines equity and debt to provide a lower cost of capital and a less dilutive arrangement. Invuity is a San Francisco, CA-based developer of surgical visualization and illumination technology aimed at improving visualization in minimally invasive surgeries. Led by CEO Philip Sawyer, the company integrates its proprietary Eigr™ illumination technology into advanced access systems for a variety of surgical specialties. Its product portfolio combines illumination and access tools to support surgeons across specialties. In June 2012 the company closed a $25M Series D financing. Invuity intends to use the funding to expand development, manufacturing and commercialization efforts for its medical devices. In conjunction with the financing, Eric Roberts from Valence Advantage will join the company’s Board of Directors.

Total raised

$81M

Funding rounds

4

Latest round

Equity

Latest activity

Feb 2015